Immune Checkpoint Myocarditis from Adjuvant Treatment of Melanoma

Review Data

Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for

researchers?

A: Very good

Abstract & Keywords

Q: Are all required components included in the abstract? Are the keywords appropriately chosen?

A: Good

Comments: Keywords are not provided in the manuscript.

Goal

Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?

A: Good

Structure

Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?

A: Good

Tools and Methods

Q: Are methods the author uses adequate and well used?

A: Good

Discussion & Conclusion

Q: Is it related to the results presented before? Do you consider them as coherent?

A: Very good

Comments: The case description is adequate. The Discussion section elucidates the importance of careful monitoring and prompt treatment in cases of cancer patients who develop life-threatening immune-related adverse events (irAEs) including myocarditis after immune checkpoint inhibitor (ICI) infusion. Robust research is required with the goal of minimizing the risk of this adverse reaction in patients especially with stage III cancer after the administration of ICIs.

Literature

Q: Does the author utilize relevant literature?

A: Good

Author's knowledge

Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?

A: Very good

Length

Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?

A: Good

Figures & Tables

Q: Does the author use them suitably? Are legend and notations clear?

A: Not applicable.

Writing style

Q: Is it clear and understandable?

A: Good

Further comments on the paper

Comments: This case report presents a rare case of a 70-year-old male with a history of obesity, coronary artery disease with prior stenting for angina, hypertension, hyperlipidemia and stage III melanoma. He developed myositis and myocarditis after receiving one dose of pembrolizumab, an immune checkpoint inhibitor. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer by enhancing the T-cell-mediated antitumor immune response but in this case, ICI induced autoreactive T cell-mediated inflammation-causing myocarditis after three weeks of the infusion of pembrolizumab. The patient died even after the infusion of checkpoint protein agonist. Further research is required to broaden the clinical impact of ICIs by limiting immune-related adverse events (irAEs) in patients treated with ICIs to monitor and treat stage III cancers.

Q: Would you recommend this manuscript for further publication?

A: Yes - Suitable to be published

If you have any questions and clarifications you can write to the journal.

Thanks,
Science Repository Team